Alzheimer’s disease affects an estimated 7.2 million Americans aged 65 and older, a figure expected to climb to 13.8 million by 2060. Despite decades of research into amyloid accumulation, tau pathology, oxidative stress, mitochondrial dysfunction, and chronic inflammation, the aging-related mechanisms that drive the disease remain incompletely understood. The new study homes in on the brain renin-angiotensin system, a hormonal signaling network best known for blood pressure regulation but increasingly implicated in cognition, inflammation, and vascular health within the brain.

Within this system, angiotensin II acts on two principal receptor subtypes: the type 1 receptor and the type 2 receptor. Hyperactivation of the type 1 receptor has been linked to inflammation, oxidative damage, mitochondrial decline, and impaired autophagy in the brain. The type 2 receptor, by contrast, belongs to the protective arm of the system, promoting nitric oxide release, vasodilation, neurite outgrowth, and anti-inflammatory effects. Animal studies have shown that activating the type 2 receptor reduces cortical and hippocampal amyloid plaques and protects against cognitive impairment, but the downstream signaling pathways responsible remained murky.

That is where ATIP enters the picture. ATIP proteins, encoded by the MTUS1 gene through alternative splicing, bind directly to the type 2 receptor and help localize it to the cell membrane, mediating some of its functions. Expression of ATIP variants is highest in the central nervous system, and prior work has shown that upon receptor activation, ATIP forms a complex with the tyrosine phosphatase SHP-1 that translocates to the nucleus and triggers neural differentiation and protection. Given these properties, the research team hypothesized that ATIP might be a key factor connecting the protective angiotensin axis to amyloid pathology.

To test the idea, the investigators analyzed postmortem frontal cortex samples from the Rush Memory and Aging Project, an ongoing cohort study in which participants agree to annual clinical evaluations and brain donation. The sample comprised 60 older adults diagnosed with Alzheimer’s disease, evenly split between those who had used angiotensin receptor blockers, a class of blood pressure drugs that selectively blocks the type 1 receptor, and those who had not. Participants using ACE inhibitors were excluded to avoid confounding effects on renin-angiotensin signaling, and the two groups were matched for age and sex, with a mean age of roughly 90 years.

The methodological centerpiece of the study was TOMAHAQ, short for triggered by offset, multiplexed, accurate mass, high resolution, and absolute quantification. This targeted mass spectrometry technique, which combines tandem mass tags with trigger-peptide detection and sequential MS3 fragmentation, allows highly specific quantification of low-abundance proteins across many samples in a single run. Using this platform, the team successfully quantified an ATIP peptide sequence, ANLKNPQIMYLEQELESLK, in 12 of the 60 participants, and quantified the type 2 receptor peptide GNSTLATTSK in 58 participants. Amyloid-beta and tau burdens were measured by the Rush Alzheimer’s Disease Center using immunohistochemistry and image analysis across eight brain regions.

The results were striking. ATIP levels showed a significant negative correlation with amyloid-beta load in the midfrontal gyrus, where the peptides were quantified, and with amyloid scores averaged across all eight brain regions. The correlation was strong, with a Spearman coefficient of −0.837 for the midfrontal region and −0.872 for the overall score. Critically, the association endured after statistical adjustment for age and angiotensin receptor blocker use, two potential confounders. When the researchers examined users and non-users of the drugs separately, the inverse correlation persisted in both groups and appeared even more pronounced among the drug users.

Not every question was resolved. The study found no significant correlation between ATIP and type 2 receptor protein levels, and no association between ATIP and tau tangle densities. The authors offer several possible explanations: the type 2 receptor is expressed at very low levels in the adult brain and declines further with age, making accurate quantification difficult; receptor protein abundance may not track receptor activity; and ATIP may exert biological effects independent of the receptor, as suggested by mouse studies in which ATIP’s anti-inflammatory benefits persisted even when the receptor was pharmacologically blocked. Detection of the ATIP peptide itself was limited to 12 of 60 samples, reflecting the technical challenge of measuring scarce proteins in postmortem tissue, although participants with and without detectable ATIP did not differ significantly in amyloid burden.

The researchers caution that the study is exploratory, cross-sectional, and small, and that correlational findings cannot establish causality. Postmortem tissue also captures only a snapshot of dynamic processes occurring during life, and the lack of a cognitively normal control group leaves open whether low ATIP detection is specific to Alzheimer’s disease. Still, the strengths are notable: this is the first direct measurement of ATIP in human Alzheimer’s brain tissue, the design controlled for key demographic factors and drug exposure, and the observed inverse correlation was strong and robust to adjustment. If replicated in larger and more diverse cohorts with longitudinal designs and functional models, ATIP could emerge as a novel target for understanding, and potentially modulating, the amyloid pathology that lies at the heart of Alzheimer’s disease.

Subject of Research: The association between frontal cortex ATIP protein levels and amyloid-beta burden in postmortem brains of older adults with Alzheimer's disease

Article Title: Higher Frontal Cortex Angiotensin Type 2 Receptor‐Interacting Protein (ATIP) Levels Are Associated With a Lower Amyloid‐Beta Burden in Postmortem Brains of Older Adults With Alzheimer's Disease

Article References: Cosarderelioglu, C., Kreimer, S., Plaza‐Rodriguez, A. I., Iglesias, P. A., Talbot, C. C., Jr., Siragy, H. M., Ubaida‐Mohien, C., Grodstein, F., Ferrucci, L., Bennett, D. A., Walston, J., & Abadir, P. (2026). Higher Frontal Cortex Angiotensin Type 2 Receptor‐Interacting Protein ( ATIP ) Levels Are Associated With a Lower Amyloid‐Beta Burden in Postmortem Brains of Older Adults With Alzheimer's Disease. Aging Cell, 25(9), Article e70686. https://doi.org/10.1111/acel.70686

Image Credits: AI Generated

DOI: 10.1111/acel.70686

Keywords: Alzheimer's disease, ATIP, angiotensin II type 2 receptor, amyloid-beta, brain renin-angiotensin system, postmortem brain, TOMAHAQ mass spectrometry, angiotensin receptor blockers, tau pathology, neurodegeneration, aging, MTUS1 gene

Alzheimer’s disease pathogenesis is intimately connected to the accumulation of Aβ plaques in cerebral tissues, which contribute to neuronal dysfunction and cognitive decline. The glymphatic system, a recently characterized waste clearance pathway, facilitates the movement of cerebrospinal fluid (CSF) along perivascular spaces into the brain interstitium, promoting metabolic waste removal including Aβ peptides. This system relies heavily on the health of periarterial spaces and astrocytic glial cells to maintain fluid dynamics critical for neural homeostasis.

In AD patients, amyloid aggregation results in vascular stiffness and impaired cerebral artery compliance. This vascular compromise diminishes CSF influx and interstitial fluid efflux, ultimately disrupting glymphatic function. The resultant reduction in waste clearance exacerbates Aβ accumulation, propelling a vicious cycle of neurodegeneration. It is against this backdrop that lecanemab’s efficacy in ameliorating AD symptoms and pathological hallmarks has generated significant clinical interest.

The investigative team employed the diffusion tensor imaging along the perivascular space (DTI-ALPS) index, a non-invasive MRI biomarker reflecting glymphatic flow efficiency, to examine changes pre- and post-lecanemab therapy in AD patients. Contrary to expectations, evaluation three months after initiating treatment revealed no statistically significant improvement in this index, suggesting systemic glymphatic impairment persists despite amyloid plaque reduction.

This lack of short-term glymphatic restoration highlights the probable irreversible neuronal and vascular damage established early in the disease course. The findings suggest that the pathological cascade leading to glymphatic dysfunction may progress beyond a point at which amyloid removal can effectively restore clearance capacity. This revelation challenges current amyloid-centric therapeutic strategies and compels the scientific community to consider adjunct or alternative interventions targeting additional pathological pathways.

The researchers emphasize that the persistence of glymphatic impairment could account for residual cognitive decline observed in patients treated with amyloid-lowering agents like lecanemab. The disconnection between plaque burden reduction and functional recovery cautions against relying solely on anti-amyloid therapies to reverse or halt Alzheimer’s progression. Instead, a more holistic approach addressing vascular integrity, neuroinflammation, and white matter lesions may be required for meaningful clinical outcomes.

Lead graduate student Tatsushi Oura pointed out the need for further longitudinal studies exploring age-related factors, disease staging, and varying degrees of white matter pathology in shaping the glymphatic response to treatment. The objective is to delineate patient subgroups who might derive the greatest benefit from lecanemab and to optimize therapeutic timing and combination strategies accordingly.

Technically, this study leverages advanced MRI imaging and diffusion tensor analysis to quantify changes in water molecule movement patterns reflecting perivascular clearance. By mapping the diffusion anisotropy in periarterial spaces, the DTI-ALPS index serves as a valuable surrogate for glymphatic system functionality. The absence of measurable improvement despite amyloid plaque removal suggests a decoupling of two interconnected yet distinct pathological processes within AD.

The clinical implications of these results are profound. While lecanemab represents a breakthrough in amyloid-targeting disease-modifying therapies, it is increasingly apparent that multi-targeted approaches may be essential to counterbalance the diverse mechanisms driving AD progression. Early intervention before overt symptom manifestation and combined therapies addressing vascular and neuroimmune components could form the cornerstone of future treatment protocols.

This investigation also accentuates the importance of non-invasive imaging biomarkers in monitoring treatment response beyond conventional cognitive assessments. Such tools are vital for understanding the biological underpinnings of therapeutic outcomes and tailoring individualized interventions. Their integration into clinical trials may accelerate the design of more effective multi-modal therapeutic regimens.

Published in the Journal of Magnetic Resonance Imaging in September 2025, the study is a testament to the evolving landscape of Alzheimer’s research that continuously reshapes our understanding of neurodegenerative diseases. It calls attention to the need for patience and persistence in developing treatments that confront the full complexity of AD pathology rather than singular causative agents.

While amyloid-β remains a critical target in Alzheimer’s research, the glymphatic clearance system’s integral role invites a paradigm shift toward therapies that restore brain waste removal capacity and vascular health. The ongoing work by Osaka Metropolitan University’s team offers a strategic blueprint for this expanded scientific focus—one that holds promise for more effective management of Alzheimer’s disease in the future.

Subject of Research: People
Article Title: Unchanged Early Diffusion Tensor Imaging Along Perivascular Space Index After Amyloid-Targeting Disease-Modifying Therapy in Alzheimer’s Disease: A Preliminary Study
News Publication Date: September 8, 2025
Web References: http://dx.doi.org/10.1002/jmri.70118
Image Credits: Osaka Metropolitan University
Keywords: Alzheimer’s disease, lecanemab, amyloid-beta, glymphatic system, diffusion tensor imaging, DTI-ALPS index, neurodegeneration, cerebrospinal fluid clearance, amyloid plaques, vascular stiffness, disease-modifying therapy